# A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension

Study · id `cardio:ct-nct07654140` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07654140](<https://clinicaltrials.gov/study/NCT07654140>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07654140

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 252 participants.

## Technical summary

Registry record NCT07654140. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-09 (actual); primary completion 2027-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 252 participants (planned count; ClinicalTrials.gov record NCT07654140, source copy `cardio:ctgov-nct07654140-2026-06-17`, retrieved 2026-10-26)
- Started: 2025-12-09 (actual) (ClinicalTrials.gov record NCT07654140, source copy `cardio:ctgov-nct07654140-2026-06-17`, retrieved 2026-10-26)
- Primary completion: 2027-03-01 (anticipated) (ClinicalTrials.gov record NCT07654140, source copy `cardio:ctgov-nct07654140-2026-06-17`, retrieved 2026-10-26)
- Completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT07654140, source copy `cardio:ctgov-nct07654140-2026-06-17`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07654140, source copy `cardio:ctgov-nct07654140-2026-06-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07654140-2026-06-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension
- Condition: Uncontrolled Hypertension
- Intervention (Drug): SAL0140
- Intervention (Drug): SAL0140
- Intervention (Drug): SAL0140
- Intervention (Drug): Placebo
- Lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. (`cardio:org-shenzhen-salubris-pharmaceuticals-co-ltd`)

## Provenance

Content hash: ff21ee016ac1cdededc39f71f1b5031e4404bac0089ebc9225fb183f05d30fe9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
